Verdiperstat ( DrugBank: Verdiperstat )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
2	筋萎縮性側索硬化症	2
17	多系統萎縮症	7
127	前頭側頭葉変性症	1

2. 筋萎縮性側索硬化症

臨床試験数 : 624 / 薬物数 : 611 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04436510 (ClinicalTrials.gov)	July 28, 2020	1/6/2020	HEALEY ALS Platform Trial - Regimen B Verdiperstat	HEALEY ALS Platform Trial - Regimen B Verdiperstat	Amyotrophic Lateral Sclerosis	Drug: Matching Placebo;Drug: Verdiperstat	Merit E. Cudkowicz, MD	Biohaven Pharmaceuticals, Inc.	Active, not recruiting	18 Years	N/A	All	167	Phase 2/Phase 3	United States
2	NCT04297683 (ClinicalTrials.gov)	July 14, 2020	3/3/2020	HEALEY ALS Platform Trial - Master Protocol	HEALEY ALS Platform Trial	Amyotrophic Lateral Sclerosis	Drug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 Trehalose	Merit E. Cudkowicz, MD	Massachusetts General Hospital	Recruiting	18 Years	N/A	All	800	Phase 2/Phase 3	United States

First Previous1Next Last

17. 多系統萎縮症

臨床試験数 : 118 / 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112

diseases per page:

Showing 1 to 7 of 7 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04616456 (ClinicalTrials.gov)	December 30, 2020	26/10/2020	Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients	Effect of Verdiperstat on Microglial Activation in Well-characterized MSA Patients	Multiple System Atrophy;Multiple System Atrophy, Cerebellar Variant;Multiple System Atrophy, Parkins ...	Drug: [F-18]PBR06;Drug: Verdiperstat	Brigham and Women's Hospital	Biohaven Pharmaceuticals, Inc.	Active, not recruiting	18 Years	N/A	All	25	Early Phase 1	United States
2	EUCTR2019-001100-38-IT (EUCTR)	19/02/2020	26/01/2021	A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple Sy ...	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Product Name: BHV-3241 Product Code: [/] INN or Proposed INN: Verdiperstat	Biohaven Pharmaceuticals, Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252	Phase 3	France;United States;Austria;Germany;United Kingdom;China;Italy
3	EUCTR2019-001100-38-DE (EUCTR)	07/01/2020	07/10/2019	A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple Sy ...	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Product Name: BHV-3241 INN or Proposed INN: Verdiperstat	Biohaven Pharmaceuticals, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	422	Phase 3	United States;France;Austria;Germany;United Kingdom;Italy;China
4	EUCTR2019-001100-38-AT (EUCTR)	20/12/2019	29/10/2019	A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple Sy ...	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Product Name: BHV-3241 INN or Proposed INN: Verdiperstat	Biohaven Pharmaceuticals, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	422	Phase 3	United States;France;Austria;Germany;United Kingdom;Italy;China
5	EUCTR2019-001100-38-FR (EUCTR)	13/12/2019	03/10/2019	A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple Sy ...	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Product Name: BHV-3241 INN or Proposed INN: Verdiperstat	Biohaven Pharmaceuticals, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	252	Phase 3	United States;France;Austria;Germany;Italy;United Kingdom
6	EUCTR2019-001100-38-GB (EUCTR)	06/12/2019	11/10/2019	A study to assess whether a drug called BHV-3241 works and is safe to use in people with Multiple Sy ...	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safe ...	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple s ...	Product Name: BHV-3241 INN or Proposed INN: Verdiperstat	Biohaven Pharmaceuticals, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	422	Phase 3	United States;France;Austria;Germany;Italy;United Kingdom
7	NCT03952806 (ClinicalTrials.gov)	July 29, 2019	15/5/2019	Study of BHV-3241 in Subjects With Multiple System Atrophy	A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and S ...	Multiple System Atrophy	Drug: Verdiperstat;Drug: Placebo	Biohaven Pharmaceuticals, Inc.	NULL	Active, not recruiting	40 Years	80 Years	All	336	Phase 3	United States;Austria;France;Germany;Italy;United Kingdom

First Previous1Next Last

先頭へ

127. 前頭側頭葉変性症

臨床試験数 : 89 / 薬物数 : 104 - (DrugBank : 33) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 117

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05184569 (ClinicalTrials.gov)	January 20, 2022	17/12/2021	Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology	Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharm ...	Semantic Dementia	Drug: Verdiperstat	Peter Ljubenkov, MD	National Institutes of Health (NIH);Alzheimer's Association;National Institute on Aging (NIA)	Not yet recruiting	18 Years	85 Years	All	64	Phase 1	NULL

First Previous1Next Last

先頭へ